Commonwealth of Massachusetts Center for Health Information & Analysis (CHIA) Non-Government Agency Application for Data

This application is to be used by all applicants, except Government Agencies, as defined in 957 CMR 5.02.

<u>NOTE</u>: In order for your application to be processed, you must submit the required application fee. Please consult the fee schedules for APCD and Case Mix data for the appropriate fee amount. A remittance form with instructions for submitting the application fee is available on the CHIA website.

I. GENERAL INFORMATION

APPLICANT INFORMATION	
Applicant Name:	Susan K. Parsons, MD, MRP
Title:	Professor of Medicine and Pediatrics at Tufts
	University School of Medicine; Medical Director,
	Reid R. Sacco Adolescent and Young Adult
	Program for Cancer and Hereditary Blood
	Diseases
Organization:	Tufts Medical Center
Project Title:	Cost Effectiveness of Novel Oncolytics in Newly
	Diagnosed Hodgkin Lymphoma: External
	Validation Study using APCD
Date of Application:	July 28, 2014
Project Objectives (240 character limit)	Evaluate patterns of healthcare utilization and
	components of cost among patients with
	Hodgkin Lymphoma and determine cost
	modifiers and variability in spending by socio-
	demographic, clinical, and payer
	characteristics.
Project Research Questions (if applicable)	1.
	2.
	3.

I. PROJECT SUMMARY

Briefly describe the purpose of your project and how you will use the requested CHIA data to accomplish your purpose.

While the majority of patients with Hodgkin Lymphoma (HL) have high rates of treatment success, a subset of patients still experience treatment failure, requiring salvage therapy and, often, hematopoietic cell transplantation (HSCT). Moreover, although cured of their disease, many HL survivors have substantially elevated mortality rates in the decades following treatment due to second cancers and end organ damage. Thus, the major challenge in the development of modern therapies is to optimize the balance between maintaining excellent disease control and minimizing treatment-related burden. Improved risk stratification methods, the addition of novel targeted approaches to radiation therapy, and incorporation of a novel oncolytic into the backbone of chemotherapy are all under evaluation to attain this balance. The cost effectiveness of a novel oncolytic is being examined in two ongoing Phase III trials—one for adults and another for children and adolescent. Our study team is leading the cost effectiveness for the latter study. The purpose of our APCD data request is to facilitate an analysis of

cost of standard therapy in the real world. The APCD data will allow us to delineate cost components during the initial treatment period and estimates of cost due to treatment failure, requiring salvage chemotherapy and possibly, HSCT. We will be collecting units of healthcare utilization in the clinical trial. We propose to assign population-level cost estimates to this healthcare utilization, using the APCD. We will also look at modifiers of cost and variability in spending by socio-demographic characteristics, comorbidity, and insurance. Population-level estimates of healthcare utilization, costs, and associated patterns of care are currently not available for children, adolescent, and adult HL patients. The project is being funded by the Leukemia & Lymphoma Society. We are not subject to any contractual conditions on publication or dissemination of findings.

II. FILES REQUESTED

Please indicate the databases from which you seek data, the Level(s) and Year(s) of data sought.

ALL PAYER CLAIMS DATABASE	Level 1 ¹ or 2 ²	Single or Multiple Use	Year(s) Of Data Requested Current Yrs. Available 2009 - 2012
Medical Claims	Level 1 ³ Level 2	Single ▼	2009 2010 2011 2012
Pharmacy Claims	Level 2	Single	2009 2010 2011 2012
Dental Claims Member Eligibility Provider Product	Level 2 Level 2 Level 2 Level 2 Level 2 Level 2	Select ▼ Single ▼ Single ▼ Select ▼	2 2009 2 2010 2 2011 2 2012

CASEMIX	Level 1 - 6	Fiscal Years Requested
	Level 1 – No Identifiable Data Elements	<u>1998-2013 Available</u> (limited data 1989-1997)
	Level 2 – Unique Physician Number (UPN)	
Inpatient Discharge	Level 3 – Unique Health Information Number (UHIN)	
,,	Level 4 – UHIN and UPN	
	Level 5 – Date(s) of Admission; Discharge; Significant Procedures	
	Level 6 – Date of Birth; Medical Record Number; Billing Number	
Outpatient Observation	Level 1 – No Identifiable Data Elements	2002-2012 Available (2013 available 8/1/14)

¹ Level 1 Data: De-identified data containing information that does not identify an individual patient and with respect to which there is no reasonable basis to believe the data can be used to identify an individual patient. This data is de-identified using standards and methods required by HIPAA.

² Level 2 (and above) Data: Includes those data elements that pose a risk of re-identification of an individual patient.

³ Please note that Level 1 APCD data is not available as of 4/30/2014. This is scheduled to be available later in 2014.

APCD Release Version 2.1 – Application Published 05.13.2014 Level 2 – Unique Physician Number (UPN) Level 3 – Unique Health Information Number (UHIN) Level 4 - UHIN and UPN Level 5 – Date(s) of Admission; Discharge; Significant Procedures Level 6 - Date of Birth; Medical Record Number; Billing Number 2000-2012 Available Level 1 – No Identifiable Data Elements (2013 available 9/1/14) Level 2 – Unique Physician Number (UPN) Level 3 - Unique Health Information Number (UHIN) **Emergency** Department Level 4 - UHIN and UPN; Stated Reason for Visit Level 5 – Date(s) of Admission; Discharge; Significant Procedures Level 6 - Date of Birth; Medical Record Number; Billing Number **III. FEE INFORMATION**

Please consult the fee schedules for APCD (Administrative Bulletin 13-11) and Case Mix data (Administrative Bulletin 13-09) and select from the following options:

APCD Applicants Only

χ

Χ	Academic Researcher
	Others (Single Use)
	Others (Multiple Use)
•	national distribution of
case	Mix Applicants Only
	Single Use
	Limited Multiple Use
	Multiple Use
Are v	ou requesting a fee waiver?
\sqcap	Yes

No

If yes, please submit a letter stating the basis for your request. Please refer to the fee schedule for qualifications for receiving a fee waiver. If you are requesting a waiver based on the financial hardship provision, please provide documentation of your financial situation. Please note that non-profit status alone isn't sufficient to qualify for a fee waiver.

IV. REQUESTED DATA ELEMENTS [APCD Only]

State and federal privacy laws limit the use of individually identifiable data to the minimum amount of data needed to accomplish a specific project objective. Please use the APCD Data Specification Workbook to identify which data elements you would like to request and attach this document to your application.

Federal law (42 USC 1396a(a)7) restricts the use of individually identifiable data of Medicaid recipients to uses that a directly connected with the administration of the Medicaid program. If you are requesting Medicaid data from Leve or above, please describe in detail why your use of the data meets this requirement. Applications requesting Medica data will be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly connected to the administration of the Medicaid program. MassHealth may impose additional requirements on applicants for Medicaid data as necessary to ensure compliance with federal laws and regulations regarding Medicaid. National data suggest that approximately 1/4 of adults and 1/3 of children/adolescents with HL are insured by Medicaid. Including the Medicaid claims in the APCD allows us to capture overall cost and	\/ N	APCD Release Version 2.1 – Application Published 05.13.20
X Yes No Federal law (42 USC 1396a(a)7) restricts the use of individually identifiable data of Medicaid recipients to uses that a directly connected with the administration of the Medicaid program. If you are requesting Medicaid data from Leve or above, please describe in detail why your use of the data meets this requirement. Applications requesting Medicada will be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly connected to the administration of the Medicaid program. MassHealth may impose additional requirements on applicants for Medicaid data as necessary to ensure compliance with federal laws and regulations regarding Medicaid. National data suggest that approximately 1/4 of adults and 1/3 of children/adolescents with HL are insured by Medicaid. Including the Medicaid claims in the APCD allows us to capture overall cost and		- · · · · · · · · · · · · · · · · · · ·
Federal law (42 USC 1396a(a)7) restricts the use of individually identifiable data of Medicaid recipients to uses that a directly connected with the administration of the Medicaid program. If you are requesting Medicaid data from Leve or above, please describe in detail why your use of the data meets this requirement. Applications requesting Medica data will be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly connected to the administration of the Medicaid program. MassHealth may impose additional requirements on applicants for Medicaid data as necessary to ensure compliance with federal laws and regulations regarding Medicaid. National data suggest that approximately 1/4 of adults and 1/3 of children/adolescents with HL are insured by Medicaid. Including the Medicaid claims in the APCD allows us to capture overall cost and		, -
Federal law (42 USC 1396a(a)7) restricts the use of individually identifiable data of Medicaid recipients to uses that a directly connected with the administration of the Medicaid program. If you are requesting Medicaid data from Leve or above, please describe in detail why your use of the data meets this requirement. Applications requesting Medica data will be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly connected to the administration of the Medicaid program. MassHealth may impose additional requirements on applicants for Medicaid data as necessary to ensure compliance with federal laws and regulations regarding Medicaid. National data suggest that approximately 1/4 of adults and 1/3 of children/adolescents with HL are insured by Medicaid. Including the Medicaid claims in the APCD allows us to capture overall cost and	_	
directly connected with the administration of the Medicaid program. If you are requesting Medicaid data from Leve or above, please describe in detail why your use of the data meets this requirement. Applications requesting Medica data will be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly connected to the administration of the Medicaid program. MassHealth may impose additional requirements on applicants for Medicaid data as necessary to ensure compliance with federal laws and regulations regarding Medicaid. National data suggest that approximately 1/4 of adults and 1/3 of children/adolescents with HL are insured by Medicaid. Including the Medicaid claims in the APCD allows us to capture overall cost and	Ш	No
insured by Medicaid. Including the Medicaid claims in the APCD allows us to capture overall cost and		,
·	or ab data conn	please describe in detail why your use of the data meets this requirement. Applications requesting Medicaid be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly d to the administration of the Medicaid program. MassHealth may impose additional requirements on
and the control of brightness of the left and the control of the c	or ab data conn	please describe in detail why your use of the data meets this requirement. Applications requesting Medicaid be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly do to the administration of the Medicaid program. MassHealth may impose additional requirements on a for Medicaid data as necessary to ensure compliance with federal laws and regulations regarding Medicaid.
cost components of nealthcare utilization in this critical population. Excluing this population from the	or ab data conn	please describe in detail why your use of the data meets this requirement. Applications requesting Medicaid be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly do to the administration of the Medicaid program. MassHealth may impose additional requirements on a for Medicaid data as necessary to ensure compliance with federal laws and regulations regarding Medicaid.
analysis would result in biased estimates. Moreover, inclusion of these claims will allow us to analyze	or ab data conn	please describe in detail why your use of the data meets this requirement. Applications requesting Medicaid be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly do to the administration of the Medicaid program. MassHealth may impose additional requirements on a for Medicaid data as necessary to ensure compliance with federal laws and regulations regarding Medicaid.
cost modifiers and variability in spending by socio-demographic characteristics and payer status.	or ab data conn	please describe in detail why your use of the data meets this requirement. Applications requesting Medicaid be forwarded to MassHealth for a determination as to whether the proposed use of the data is directly do to the administration of the Medicaid program. MassHealth may impose additional requirements on a for Medicaid data as necessary to ensure compliance with federal laws and regulations regarding Medicaid. Second data suggest that approximately 1/4 of adults and 1/3 of children/adolescents with HL are sured by Medicaid. Including the Medicaid claims in the APCD allows us to capture overall cost and lost components of healthcare utilization in this critical population. Excluing this population from the

VI. REQUESTS PURSUANT TO 957 CMR 5.04

If you are a payer, provider, provider organization or researcher seeking access to Level 1 (de-identified) data, please describe how you will use such data for the purposes of lowering total medical expenses, coordinating care, benchmarking, quality analysis or other administrative research purposes. Please provide this information below.

VII. FILTERS

If you are requesting APCD elements from Level 2 or above, describe any filters you are requesting to use in order to limit your request to the minimum set of records necessary to complete your project. (For example, you may only need individuals whose age is less than 21, claims for hospital services only, or only claims from small group projects.)

APCD FILE	DATA ELEMENT(S) FOR WHICH FILTERS ARE REQUESTED	RANGE OF VALUES REQUESTED
Medical Claims		
Pharmacy Claims		
Dental Claims		
Membership Eligibility		
Provider		
Product		

VIII. PURPOSE AND INTENDED USE

1. Please explain why completing your project is in the public interest.

This database analysis and the ongoing cost effectiveness analysis of the inclusion of a novel oncolytic in

the treatment of HL will provide stakeholders—patients and their families, physicians, payers, and policy makers—with the much needed information about overall costs and benefits of alternative treatment approaches. The focus of this cost comparison will be the initial years following diagnosis.

	2.	Attach a brief (1-2 pages) description of your research methodology. (This description will not be posted on the internet.)
	3.	Has your project received approval from your organization's Institutional Review Board (IRB)? Please note that CHIA will not review your application until IRB documentation has been received (if applicable).
		Yes, and a copy of the approval letter is attached to this application.
		No, the IRB will review the project on
		No, this project is not subject to IRB review.
		No, my organization does not have an IRB.
IX. AI		CANT QUALIFICATIONS
	1.	Describe your qualifications to perform the research described or accomplish the intended use of CHIA data.
	add in h car hei	Parsons, a board certified pediatric hematologist/oncologist, specializes in the treatment of children, plescents, and young adults with hematologic malignancies, including HL. She is also formally trained nealth economics and has spent her career analyzing the financial and functional consequences of near care. To conduct the proposed analyses she has assembled a project team including experts in matologic malignancies and survivorship, in addition to health economists with expertise in the alysis of administrative claims data.
	2.	Attach résumés or curricula vitae of the applicant/principal investigator, key contributors, and of all individuals who will have access to the data. (These attachments will not be posted on the internet.)
X. DA	TA L	INKAGE AND FURTHER DATA ABSTRACTION
	[Does your project require linking the CHIA Data to another dataset? □Yes (No
	[If yes, will the CHIA Data be linked to other patient level data or with aggregate data (e.g. Census data)? □ Patient Level Data □ Aggregate Data
	3.	If yes, please identify all linkages proposed and explain the reasons(s) that the linkage is necessary to accomplish the purpose of the project. Please be specific in describing vwhich data elements will be linked to outside datasets and how this will be accomplished.
	N/A	

		 If yes, please identify the specific steps you will take to prevent the identificatio the linked dataset. 	n of individual patients ir
		N/A	
XI.		PUBLICATION / DISSEMINATION / RE-RELEASE 1. Describe your plans to publish or otherwise disclose CHIA Data, or any data derived	
		in any paper, report, website, statistical tabulation, seminar, conference, or other se Results of the analyses will be published in journals or discussed at conferences or m	
	2.	 Will the results of your analysis be publicly available to any interested party? Please party will obtain your analysis and, if applicable, the amount of the fee. 	
		The results of our analysis will be available publicly in the form of publications in jou conferences and meetings.	rnals or at
	3. \[\] \	—	
	4. \[\] X	☐ Yes	
	5. □ X	☐ Yes	
	6.	6. If you have answered "yes" to questions 3, 4 or 5, please describe the types of produ	ıcts, services or studies.
		N/A	
XII.	. U:	USE OF AGENTS AND/OR CONTRACTORS	
<u>Thi</u>	rd-P	d-Party Vendors. Provide the following information for all agents and contractors who w	vill work with the CHIA Da
		Company Name:	
		Contact Person:	
		Title:	
		Address:	
		Telephone Number:	
		E-mail Address:	
		Organization Website:	
		• · · · · · · · · · · · · · · · · · · ·	

7.	Will the agent/contractor have access to the data at a location other than your location or in an off-site server and/or database?
	☐ Yes ☐ No
8.	Describe the tasks and products assigned to this agent or contractor for this project.
9.	Describe the qualifications of this agent or contractor to perform such tasks or deliver such products.
10.	Describe your oversight and monitoring of the activity and actions of this agent or subcontractor.